Advertisement

---

VELOXIS

Veloxis Announces Positive Results of 3002 Study: LCP-Tacro™ Meets Primary Efficacy and Safety Endpoints in de Novo Kidney Transplant Patients

[2013-06-27] - - LCP-Tacro™, once-daily, demonstrated non-inferiority to Prograf®, twice-daily, based on the composite endpoint of treatment failure at one year (LCP-Tacro™ 18.3%, Prograf® 19.6%)
- Treatment failure rates through the first three months after transplant were 10.4% for LCP-Tacro™ and 14.2% for Prograf®
- Similar incidence of adverse events and impact on laboratory results reported for LCP-Tacro™ and Prograf®
- Regulatory submission to the FDA on track for second half of 2013
- Conference call to discuss the results will be held on 28 June at 8 a.m. CEDT (2 a.m. EDT)


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers